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1. Introduction  
The lysosomal storage disorders (LSDs) are a group of almost 50 genetic diseases, 
characterized by mutations and loss of activity of lysosomal enzymes or, less frequently, 
non-lysosomal proteins that are involved in protein maturation or lysosomal biogenesis 
(Meikle et al, 2004).  Most LSDs have an autosomal recessive inheritance, with  
some exceptions as Hunter syndrome (X-linked recessive), Danon disease (X-linked 
dominant) and Fabry disease (X-linked with a high proportion of heterozygous affected 
females).  
Storage of distinct undegraded or partially degraded material, usually the substrate of the 
defective enzyme, occurs in the lysosome. The substrate type is used to group the LSDs into 
general categories (table 1), including mucopolysaccharidoses (characterized by the storage 
of mucopolysaccharides, also called glycosaminoglycans), lipidoses (storage of lipids), 
glycogenoses (storage of glycogen) and oligosaccharidoses (storage of small sugar chains). 
Despite this categorization, many clinical similarities are observed between groups as well 
as within each group. Generally these diseases are multisystemic, and clinical features of 
many LSDs include organomegaly, central nervous system dysfunction and coarse hair and 
faces. Most LSDs are characterized by their progressive course with high morbidity and 
increased mortality, although there are significant variations between different diseases, and 
even among patients with the same disease (Walkley 2009). Lysosomal enzymes are 
ubiquitously distributed, but substrate storage is usually restricted to cells, tissues and 
organs with higher substrate turnover.  
Recently, it has been suggested that the primary gene defect and substrate storage are 
triggers of a complex cascade of events that lead to many of the disease manifestations 
(Bellettato & Scarpa, 2010). In this context, secondary substrate storage, perturbations of 
Calcium homeostasis and lipid trafficking would contribute to disease pathogenesis. 
Other manifestations, related to the lysosome’s role in vescicle trafficking, including 
antigen presentation, innate immunity, and signal transduction would cause 
inflammatory and auto-immune disturbances observed in the LSD (Parkinson-Lawrence 
et al., 2010). In addition, general mechanisms such as unfolded protein response, 
reticulum stress, oxidative stress and autophagy blockade would also play a role in the 
pathogenesis (Vitner et al., 2010). 
The incidence and prevalence of these diseases varies from different countries and regions. 
For example, the overall incidence of GM1 Gangliosidosis is considered to be 1:100,000-
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1:200,000, however in some countries as Malta (1:3,700) and the South of Brazil (1:13,317) it 
is considerably higher (Baiotto et al, 2011). Large population studies suggest that the overall 
incidence of the LSDs vary from 1:5,000- 1:7,700 (Fuller et al, 2006). 
The treatment options available for the LSDs were restricted to support measures until a few 
decades ago. Nowadays, specific treatments are available for a certain number of LSDs, even 
though some of them are still in the experimental phase or have limited effects. Treatment 
options listed in table 1 consider those already approved or under clinical trial, including 
compassionate use. Support measures and palliative care are not considered treatment 
options in this context. 
  
Disease OMIM Gene Enzyme 
Available 
Treatments 
Aspartylglucosaminuria 208400 AGA 
N-aspartyl-beta-
glucosaminidase 
HSCT 
Canavan disease 271900 ASPA Aspartocylase None 
Cystinosis 219800 CTNS Cystinosin 
Cysteamine 
(drug) 
Danon disease 300257 LAMP2 
Lysosomal-associated 
membrane protein 2 
None 
Fabry disease 301500 GLA Α-galactosidase A ERT 
Farber disease 228000 ASAH1 Ceramidase HSCT 
Fucosidosis 230000 FUCA1 ǂ-L-fucosidase HSCT 
Galactosialidosis 256540 CTSA Cathepsin A None 
Gaucher disease 230800 GBA acid ǃ-glucosidase ERT, GT, HSCT,  
PCT, SSI 
GM1 gangliosidosis 230600 GLB1 ǃ-Galactosidase HSCT 
Krabbe disease 245200 GALC galactocerebrosidase HSCT 
Lysosomal Acid Lipase 
Deficiency 
278000 LIPA Lysosomal acid lipase HSCT 
ǂ- mannosidosis 248500 MAN2B1 ǂ -D -mannosidase HSCT 
ǃ- mannosidosis 248510 MANBA ǃ -D-mannosidase None 
Metachromatic 
leucodystrophy 
250100 ARSA Arylsulphatase-A HSCT 
Metachromatic 
leucodystrophy 
249900 ARSA Saposin-B HSCT 
Mucolipidosis type I 256550 NEU1 Sialidase None 
Mucolipidosis types II/III 252500 GNPTAB 
N-acetylglucosamine-1-
phosphotransferase 
None 
Mucolipidosis type IIIC 252605 GNPTG 
N-acetylglucosamine-1-
phosphotransferase Ǆ-
subunit 
None 
Mucolipidosis type IV 252650 MCOLN1 Mucolipin 1 None 
Mucopolysaccharidosis 
type I 
607014 IDUA ǂ-L-iduronidase ERT, HSCT 
Mucopolysaccharidosis 
type II 
309900 IDS Iduronate sulfatase ERT, GT, HSCT 
Mucopolysaccharidosis 
type IIIA 
252900 SGSH Heparan-N-sulfatase None 
Mucopolysaccharidosis 
type IIIB 
252920 NAGLU 
ǂ- N-
acetylglucosaminidase 
None 
Mucopolysaccharidosis 252930 HGSNAT AcetylCoa-glucosamine-N- None 
www.intechopen.com
 Non Viral Gene Transfer Approaches for Lysosomal Storage Disorders 
 
149 
type IIIC acetyltransferase 
Mucopolysaccharidosis 
type IIID 
252940 GNS 
N-acetylglucosamine-6-
sulfatase 
None 
Mucopolysaccharidosis 
type IVA 
253000 GALNS 
N-acetylgalactosamine-6-
sulphatase 
ERT 
Mucopolysaccharidosis 
type IVB 
253010 GLB1 ǃ-Galactosidase None 
Mucopolysaccharidosis 
type VI 
253200 ARSB 
N-acetylgalactosamine-4-
sulphatase 
ERT 
Mucopolysaccharidosis 
type VII 
253220 GUSB ǃ-Glucuronidase None 
Mucopolysaccharidosis 
type IX 
601492 HYAL1 Hyaluronidase None 
Multiple sulphatase 
deficiency 
272200 SUMF1 
Formylglicine-generating-
enzyme 
None 
Neuronal ceroid 
lipofuscinosis 1 
256730 PPT1 
Palmitoyl protein 
thioesterase-1 
HCST 
Neuronal ceroid 
lipofuscinosis 2 
204500 TPP1 Tripeptydil-peptidase I GT 
Neuronal ceroid 
lipofuscinosis 3 
204200 CLN3 CLN3 protein None 
Neuronal ceroid 
lipofuscinosis 5 
256731 CLN5 CLN5 protein None 
Neuronal ceroid 
lipofuscinosis 6 
601780 CLN6 CLN6 protein None 
Neuronal ceroid 
lipofuscinosis 8 
600143 CLN8 CLN8 protein None 
Niemann-Pick disease 
A/B 
257200 SMPD1 Acid sphingomyelinidase None 
Niemann-Pick disease C1 257220 NPC1 NPC1 protein SSI 
Niemann-Pick disease C2 607625 NPC2 NPC2 protein SSI 
Pompe disease 232300 GAA Alpha-glucosidase ERT, GT 
Prosaposin deficiency 176801 PSAP Prosaposin None 
Pycnodysostosis 265800 CTSK Cathepsin K 
Hormone 
therapy 
Sandhoff disease 268800 HEXB Hexosaminidase B PCT 
Schindler disease 609241 NAGA 
Alpha-N-
acetylgalactosaminidase 
None 
Sialic acid storage disease 269920 SLC17A5 Sialin None 
Sialuria 269921 GNE 
UDP-N-
acetylglucosamine-2-
epimerase 
None 
Tay-Sachs disease 272800 HEXA Hexosaminidase A PCT, SSI 
Abbreviations: GT – Gene Therapy; HSCT – Hematopoetic Stem Cell Transplantation;  
PCT – Pharmacological Chaperone Therapy; OMIM – Online Mendelian Inheritance in Man;  
SSI – Specific Substrate Inhibition; ERT – Enzyme Replacement Therapy 
Table 1. List of lysosomal storage diseases with their respective OMIM accession number, 
gene and enzyme deficiency and treatment options (including experimental ones). 
The two most widely used treatment options are Hematopoietic Stem Cell 
Transplantation (HSCT) and Enzyme Replacement Therapy (ERT). HSCT has proven to be 
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efficient to some of these diseases, especially if performed early enough to prevent 
irreversible lesions. Nevertheless, limitations such as the need of an early diagnosis, the 
difficulties to find a compatible donor in short time, and the high rates of morbidity and 
mortality associated with the procedure still limit this type of treatment (Malatack et al, 
2003). Therefore, despite the many advances in this treatment over the last 30 years 
(Boelens et al 2010), its use has been deferred in favor of ERT whenever it is available. 
Enzyme replacement therapy is approved for a growing number of LSD, especially those 
without CNS involvement. It has proven to reduce some visceral symptoms as 
hepatosplenomegaly and improve respiratory function (Sifuentes et al, 2007), however 
difficult-to-reach organs such as the brain and the bones are still a major challenge. 
Innovative routes of enzyme delivery have been tested to achieve the CNS, such as 
intrathecal ERT (Munoz-Rojas et al, 2008; Munoz-Rojas et al, 2010).  
Other treatment approaches already under clinical use or experimentation are Specific 
Substrate Inhibition (SSI) and Pharmacological Chaperone Therapy (PCT). SSI aims to 
decrease the storage by reducing substrate synthesis through an inhibitor. PCT uses small 
molecules able to stabilize the mutant enzyme and help it escape proteasomal degradation, 
thus restoring some residual enzyme activity. All such treatments have limitations (table 2), 
that justify the development of gene therapy approaches for these diseases. 
 
Approach Brief Description Pros Limitations 
Intravenous enzyme 
replacement therapy 
Intravenous injection of a 
recombinant version of 
the missing enzyme 
Ameliorates several 
visceral symptoms 
High cost 
Does not correct 
difficult-to-reach sites 
Need of repeated 
injections 
Intrathecal enzyme 
replacememnt 
therapy 
Intrathecal injection of a 
recombinant version of 
the missing enzyme 
Reaches the CNS 
High Cost 
Need of repeated 
injections 
Efficacy uncertain 
Hematopoietic stem 
cell tranplantation 
Non-autologous 
transplantation of CD 
34+ cells 
Able to correct visceral 
and CNS symptoms if 
performed early 
Limited efficacy 
Relatively high 
morbidity and 
mortality rates 
Specific substrate 
inhibition 
Use of drugs that can 
inhibit the synthesis of 
the undegraded material
Orally administered 
Reaches the CNS 
Limited efficacy 
High cost 
Pharmacological 
chaperone therapy 
Drugs that can stabilize 
the mutated protein, 
allowing some enzyme 
activity
Orally administered 
Reaches the CNS 
Works only in patients 
with specific mutations 
Stop-codon read-
through therapy 
Use of molecules that can 
suppress stop-codon 
mutations 
Orally administered 
Reaches the CNS 
Low cost 
Works only in stop-
codon mutations 
Clinical trials yet to be 
performed 
Gene Therapy 
Administration of a 
normal copy of the 
mutated gene
Potentially effective with 
single injection 
Safety concerns 
Efficacy uncertain 
Abbreviations: CNS – Central Nervous System 
Table 2. Pros and limitations of different therapeutic approaches for lysosomal storage 
diseases. 
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2. Rationale for gene therapy in LSDs 
The rationale for gene therapy and other enzyme-based approaches for treatment of LSDs 
was first introduced almost five decades ago by Christian de Duve, and can be summarized 
in the following sentence from his original work "In our pathogenic speculations and in our 
therapeutic attempts, it may be well to keep in mind that any substance which is taken up 
intracellularly in an endocytic process is likely to end up within lysosomes.” (de Duve, 
1964). His work and other pioneer studies showing cross-correction between fibroblasts 
from patients with Mucopolysaccharidosis type I and type II (deficient in alpha-L-
iduronidase and iduronate-sulphatase, respectively) established that the enzyme produced 
in one cell could be uptaken by a deficient cell, thus restoring its phenotype (Fratantoni et al, 
1968). Later studies identified that this uptake was a saturable, receptor-mediated process, 
and the main actor of this process was the mannose-6-phosphate (M6P) receptor localized in 
the plasmatic membrane. The post-translational modification of addition of the M6P to the 
protein was discovered to be a signal not only to endocytosis but also for targeting nascent 
hydrolases to lysosomes (Fisher et al, 1980; Sly et al., 1981). 
These pivotal discoveries in the field of endocytosis and targeting of lysosomal enzymes 
provided the basis for treatments like HSCT and ERT. In the same way, LSDs may be 
considered good targets for gene therapy, despite their multisystemic involvement. The 
correction of a few cells could lead to the enzyme being secreted into the circulation and 
uptaken by the deficient cells, resulting in widespread correction of the biochemical defect 
(figure 1). 
Since long term gene expression is desirable, most clinical and preclinical trials used viral 
based vectors. Initial studies on fibroblasts showed promising data using retroviruses 
(Anson et al, 1992). However, when tests in animal models started, it became clear that some 
organs as the brain would not be easily corrected, as the enzyme could not cross the blood-
brain-barrier (Elinwood et al, 2004).  This is a major hurdle as most LSD shows some degree 
of CNS involvement. Nevertheless, CNS targeted approaches could be envisaged to 
overcome this obstacle. For instance, Worgall et al. (2008) showed a slowing of progression 
of Neuronal Ceroid Lipofuscinosis 2 in ten children treated with serotype 2 adeno-
associated virus expressing CLN2 cDNA. Another clinical trial, for Pompe disease, also  
used adeno-associated-based vector, but in this case serotype 1 (NCT00976352- 
www.clinicaltrials.gov). Other two trials performed in the late 1990s used retroviral vectors 
for Gaucher (Dunbar et al., 1998) and Mucopolysaccharidosis type II (NCT00004454 - 
www.clinicaltrials.gov). 
Safety issues related to immune response of the adenoviral vectors (Wilson, 2009) and the 
possibility of insertional mutagenesis of the retroviral vectors (Hacein-Bey-Abina S et al., 
2008) led researchers to develop a series of studies in parallel using non-viral approaches to 
treat lysosomal storage disorders. 
3. Non-viral approaches 
Non-viral vectors have important safety advantages over viral approaches, including their 
reduced pathogenicity and capacity for insertional mutagenesis, as well as their low cost 
and ease of production (Fraga et al., 2008). The application of non-viral vectors to humans 
has, however, been held back by the poor efficiency of their delivery to cells and the 
transient expression of the transgenes. As new strategies are being developed for the  
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Fig. 1. Rationale for Gene Therapy in Lysosomal Storage Disorders: Cross-correction. The 
upper part of the figure shows two cells from a patient with LSD, with large lysosomes 
(green) due to accumulation of undegraded material. The gene transfer of a normal copy of 
the missing enzyme (red structure in the nucleus), allows the enzyme (red triangles) to be 
produced, and degrade the material accumulated in the lysosomes. Part of the enzyme is 
secreted from the recombinant cell and is captured by neighbouring cells via the mannose-6-
phosphate receptors (light blue structures located on the cell membrane), reaching the 
lysosomes and being able to correct their phenotype, in a process called cross-correction. 
Note that the cell on the right was never transduced, but is able to capture the enzyme from 
the circulation or from the neighbouring cell. 
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application of non-viral vectors as nucleic acid delivery systems (Resina et al., 2009; 
Wasungu and Hoekstra, 2006), progress is being made in the application of this kind of 
therapy to LSDs.  
3.1 Naked plasmid transfection 
The direct injection of a plasmid containing the gene of interest and the regulatory 
mechanisms to ensure its expression is the simplest form of gene therapy. It has some 
advantages over the virus mediated gene transfer systems. First, DNA preparation is simple 
and can be performed at relatively low cost. In addition, the safety concerns are much lower 
and large amounts of DNA can be transferred. However, the major limitation of this method 
is that it requires a local administration and the level of transgene expression is relatively 
low and restricted to the injection site (Glover et al., 2005).  
Hydrodynamic injection (Liu et al, 1999) is an experimental method capable to achieve 
efficient gene transfer and high level of transgene expression by systemic administration. In 
this procedure, a large volume of saline containing plasmid DNA is injected in a short 
period of time. The large volume and high injection rate forces the DNA solution into the 
liver, probably due to the permeability of liver fenestrae. A small hepatotoxicity, probably 
due to the large volume of saline, is observed and resolves within a few days. Even though 
this procedure is widely used in mice by tail vein injection, its feasibility has been 
demonstrated in larger animal models using a balloon occlusion catheter-based method to 
mimic hydrodynamic injection (Brunetti-Pierri et al, 2007; Kamimura et al, 2009). 
This approach has been used in a proof-of-concept study to show the importance of 
coexpression of the formylglycine-generating enzyme for synthesis and secretion of 
functional Arylsulfatase A in a mouse model of Metachromatic Leukodystrophy 
(Takakusaki et al., 2005). This enzyme is a posttranslational modifying enzyme essential for 
activating multiple forms of sulfatases including Arylsulfatase A and therefore limits the 
amount of functional enzyme that can be secreted from transduced cells.  
It has also been used in Mucopolysaccharidosis (MPS) type I (Camassola et al, 2005) and 
type VII (Richard et al, 2009). In the MPS I animals, storage content was reduced and 
enzyme activity was elevated in the liver and spleen. For the MPS VII model, a beneficial 
effect on the pathology was also observed, as liver-directed gene transfer led to the 
correction of secondary enzymatic elevations and to the reduction of GAGs storage in 
peripheral tissues and brain, as well as to histological correction in many tissues. 
3.2 Liposomes and nanotechnology 
Liposomes are lipid particles that resemble the cell membrane. Liposome-based gene 
delivery was first reported by Felgner in 1987, and is still one of the major techniques for 
non viral gene delivery into cells (Niidome & Huang, 2002). Lipoplexes are formed by the 
interaction of anionic nucleic acids binding to the surface of cationic lipids, forming 
multilamellar lipid–nucleic acid complexes where the negatively charged nucleic acid 
remains trapped inside the lipid bilayer (Dass, 2004). Since its discovery, different lipid 
formulations have been tested and modified. For example, stealth liposomes sterically 
stabilized with methoxypoly(ethylene glycol)distearoylphosphatidylethanolamine 
conjugates (PEG-DSPE) have long circulation half-lives following intravenous injection 
(Moreira et al., 2001). In addition, linear polycations such as linear, branched and dendritic 
vectors based on poly(ethylenimine) (PEI), poly(L-lysine) (PLL) and a range of 
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poly(ethylene glycol) (PEG) were also developed (Hunter, 2006). Although linear PEI shows 
greater in vivo efficiency because of a dynamic structure change of the complex under high 
salt concentrations as found in blood (Niidome & Huang, 2002), it also possesses greater 
toxicity (Morille et al., 2008).  
Cationic nanoemulsions have been more recently considered as potential systems for nucleic 
acid delivery. The interest in these systems is justified by the fact that they are biocompatible 
and able to form complexes with DNA protecting it from enzymatic degradation (Nam et 
al., 2009). Other practical advantages include ease of production and the potential for 
repeated administration (Al-Dorsari and Gao, 2009).  We have investigated the influence of 
phospholipids on the properties of cationic nanoemulsions/pDNA complexes. Complexes 
containing the phospholipids DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) and DSPE 
(1,2- distearoyl-sn-glycero-3- phosphoethanolamine) were less toxic in comparison with the 
formulations obtained with lecithin, DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) and 
DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine). In addition, higher amounts of 
reporter DNA were detected for the formulation obtained with the DSPC phospholipid 
(Fraga et al., in press). 
These cationic macromolecules can readily condense DNA or RNA into stable nanostructures 
for use in gene delivery (Hunter, 2006) but also for other nanotechnology-based approaches 
useful for the treatment of LSDs (Muro, 2010). Nanomaterials, as a result of their small size and 
their large surface area offer great promise for neuro-therapeutics (Ragnail et al., 2011) and 
thus may be a valid option for a large number of LSDs that affect the CNS. 
Liposome-mediated gene transfer for LSD has been performed in vitro using patient’s 
fibroblasts as target cells. Estruch et al. (2001) delivered therapeutic genes by integrin-
mediated uptake into fibroblasts from patients with Fucosidosis and Fabry disease. The 
vectors consisted of a complex of lipofectin and a peptide containing an integrin-targeting 
domain and a poly-lysine domain to which plasmid DNA was bound. Transfected cells 
produced the corresponding enzyme at levels which were 10-40% of the total activity in 
cultures of normal fibroblasts. Although 95-98% of this activity was secreted, it did not 
appear to affect the viability of the cells. Our group used Lipofectamine to transduce 
fibroblasts from GM1 Gangliosidosis patients with the beta-galactosidase gene. Treated cells 
showed 33 to 100- fold increases in enzyme activity compared to untreated fibroblasts. 
However, after seven days enzyme activity was back to uncorrected values (Balestrin et al., 
2008). When Geneticin was added to the medium (figure 2), stable expression at therapeutic 
levels was observed (mean 300 nmoles/h/mg prot) for 30 days, although at values lower 
than the normal range (mean 1,300 nmoles/h/mg prot).  
In vivo, PEG-coated liposomes have been modified with monoclonal antibodies in order to 
reach the CNS. A liposome is coated with peptidomimetic monoclonal antibodies that 
undergo receptor-mediated transcytosis across the blood-brain barrier on the endogenous 
peptide receptor transporters (Pardridge, 2007). These Trojan horses (figure 3) may use the 
insulin or transferrin receptor, and since the MAb binding site is different from the binding 
site of the endogenous ligand, there is no interference of endogenous ligand transport 
(Skarlatos et al, 1995). 
This approach has been used to deliver a non-viral plasmid DNA to the brain across the 
blood-brain-barrier after intravenous administration of liposomes coated with monoclonal 
antibody to the mouse transferrin receptor in a mouse model of Mucopolysaccharidosis type 
VII (Zhang et al, 2008). The enzyme activity was increased greater than ten-fold in brain, 
liver, spleen, lung, and kidney, but not in heart. A similar strategy has been used by Osborn 
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et al (2008) for Mucopolysaccharidosis type I, although they used a plasmid bearing a fusion 
gene consisting of Transferrin (Tf) and α-L-iduronidase. The fusion product consisted of an 
enzymatically active protein that was transported into the CNS by TfR-mediated 
endocytosis. Short-term treatment resulted in a decrease in GAGs in the cerebellum of 
Mucopolysaccharidosis type I mice. 
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Fig. 2. Stable expression of β-Galactosidase in fibroblasts from G1 Gangliosidosis patients 
after in vitro liposome-based gene transfer. Mean values of liposome-treated cells: 300 
nmoles/h/mg prot.; mean values of normal fibroblasts: 1,300 nmoles/h/mg prot.; mean 
values of affected fibroblasts: 68 nmoles/h/mg prot. (Balestrin et al., 2008). 
 
 
Fig. 3. Schematic view of a Trojan horse liposome. A stealth PEGylated liposome is 
complexed with monoclonal antibodies (MAb) that undergo receptor-mediated transcytosis 
across the blood-brain barrier.  
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3.3 Cell microencapsulation 
Cell microencapsulation is an approach in which cells are trapped in a semipermeable 
membrane, allowing the exchange of metabolites and nutrients between them and the 
external environment. The membrane prevents the access of the immune system to the cells, 
without the need for continued immunosuppression of the host (Uludag et al., 2000). 
Furthermore, this technique allows the localized and controlled release, and long term 
duration of therapeutic products derived from the microencapsulated cells (Orive et al., 
2002). Microencapsulation has become an important system for cellular preservation (Mayer 
et al., 2010) and a potential strategy for the controlled delivery of therapeutic products 
(Orive et al., 2003). Alginate has been the most important encapsulation polymer due to its 
abundance, easy gelling properties and biocompatibility. Agarose, chitosan, and hyaluronic 
acid are other polymers used for microencapsulation (Orive et al., 2003). 
Cell microencapsulation presents the potential to deliver the therapeutic product of interest 
directly to the Central Nervous System (CNS). This has been achieved by different groups 
for brain tumors (Kuijlen et al 2007) and neurodegenerative diseases (Spuch et al 2010).  A 
phase I clinical trial was conducted in Huntington’s patients without signs of toxicity (Bloch 
et al 2004). This approach delivers the gene of interest in the spinal fluid, similar to the 
intrathecal enzyme replacement therapy. Thus, cell encapsulation can be suitable for the 
treatment of LSD, once the deficient enzyme could be released for long term directly in the 
CNS (Matte et al., 2011). 
In order to obtain larger amounts of secreted enzyme, the encapsulated cells should be 
genetically modified to over-express the enzyme of interest. This enzyme would then be 
released to the extracapsular space (Bressel et al 2008) and uptaken by adjacent deficient 
cells (figure 4). This strategy has been used experimentally for different LSD, especially the 
Mucopolysaccharidosis (MPS).  
Three in vitro studies were performed in LSDs other than the MPS, one in Fabry disease and 
the other two in Metachromatic Leukodystrophy (MLD). Naganawa et al (2002) co-cultured 
fibroblasts from patients with Fabry disease with microencapsulated recombinant Chinese 
Hamster Ovary cells (CHO) over-expressing alpha-galactosidase. The deficient cells were 
able to uptake the enzyme decreasing their levels of globotriaosylceramide storage. A 
similar approach was used by our group to test the ability of Baby Hamster Kidney (BHK) 
cells over-expressing ARSA to correct the deficiency of this enzyme in human skin 
fibroblasts from MLD patients.  Fibroblasts co-cultured with the encapsulated cells for four 
weeks showed levels of enzyme activity higher than normal. Transmission electron 
microscopy showed evidence of normalization of the lysosomal ultra structure, suggesting 
that the secreted enzyme was able to degrade the substrate (Lagranha et al., 2008). Consiglio et 
al (2007) collected the conditioned media of C2C12 cells over-expressing ARSA encapsulated 
in polyether-sulfone polymer and used it to treat oligodendrocytes from MLD mice. The 
deficient cells internalized the enzyme and it was normally sorted to the lysosomal 
compartment, reaching 80% of physiological levels and restoring sulfatide metabolism. 
Both in vitro and in vivo studies have been performed in the MPS types I, II and VII. For MPS 
II two studies were performed. The first was a proof of principle in which Hunter primary 
fibroblasts were co-cultured with alginate microcapsules containing C2C12 cell clones over-
expressing IDS. After 5 days of co-culture this strategy was able to increase IDS activity 
inside the deficient fibroblasts to levels similar to normal (Tomanin et al 2002). The second 
study was a pre-clinical experiment in which APA (alginate-poli-L-lysine-alginate) 
microcapsules containing 1.5 x 106 allogeneic C2C12 myoblasts over-expressing IDS were 
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implanted in the peritoneum of the MPS II mouse model. An increase in IDS activity in 
plasma was observed, along with a reduction on urinary GAG between the fourth and the 
sixth week of treatment. After 8 weeks, a reduction of 30% in the amount of GAG 
accumulated in the liver and 38% in the kidney were shown (Friso et al 2005).  
 
 
Fig. 4. Traffic of lysosomal enzymes throughout the encapsulated cells. The nascent 
lysosomal enzymes are glycosylated in the endoplasmic reticulum (ER) of the genetically 
modified cells. (A) The enzymes are phosphorylated at the residue of mannose-6 in the 
Golgi apparatus. (B) Most enzymes are transported to mature lysosomes. (C) Some, 
however, are secreted to the extracellular environment and (D) to outside of the 
microcapsules. (E) Phosphorylated enzymes bind to mannose-6-phosphate receptors 
(M6PR) of the enzyme-deficient cells (F) where they are endocyted and subsequently 
targeted to the lysosomes (Matte et al., 2011). 
To evaluate the usefulness of this technique to treat MPS VII, Ross et al (2000a) injected APA 
encapsulated non-autologous cells overexpressing Gusb in the peritoneum of MPS VII mice. 
The results showed the presence of Gusb in the plasma 24 hours after implantation, reaching 
66% of physiological levels by 2 weeks post implantation. Activity of Gusb was also detected 
in liver and spleen for the duration of the 8-week experiment. Accumulation of GAG  
was significantly reduced in liver and spleen sections and urinary GAG content reached 
normal levels. In another study, enzyme released by APA encapsulated 2A50 fibroblasts 
implanted directly into the lateral ventricles of the brain of MPS VII mice was delivered 
throughout most of the CNS, reversing the histological pathology (Ross et al., 2000b). In vitro 
studies were performed by Nakama et al (2006) who encapsulated immortalized recombinant 
human amniotic epithelial cells with MPS VII human and mouse fibroblasts and high GUSB 
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activity was detected in the medium. Addition of mannose-6-phosphate led to decreased 
enzyme activity, suggesting that enzyme uptake was mediated by mannose-6-phosphate 
receptor.  
Our group has shown that the correction of MPS I fibroblasts by recombinant encapsulated 
BHK cells is also mediated by mannose-6-phosphate receptor. The effect of the ratio 
fibroblasts:encapsulated cells was also analysed (figure 5). The amount of enzyme uptaken 
by the fibroblasts is essentially the same under the different ratios (5:1; 1:1; 1:5) although the 
enzyme activity in the medium increases, as more enzyme is released. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. IDUA enzyme activity in MPS I fibroblasts co-cultured with recombinant BHK cells 
overexpressing IDUA at different ratios. 
Our results also showed an increase in IDUA activity in MPS I fibroblasts after 15, 30 and 45 
days of co-culture with the capsules. Cytological analysis showed a marked reduction in 
GAG storage within MPS I cells (Baldo et al., 2011). Ongoing experiments are under way in 
the MPS I mouse model. The capsules were implanted in the peritoneum (figure 6) and 
animals were sacrificed at 4 months later. Histological analysis showed a reduction on GAG 
storage although plasma and tissue enzyme activity levels were not increased.  
These results are quite different from those of Barsoum et al (2003) who implanted 
genetically modified Madin-Darby canine kidney cells (MDCK) over-expressing canine 
Idua in the brain parenchyma of one MPS I dog. Enzyme in plasma and cerebrospinal 
fluid was low but detectable for 21 days. Immunohistochemistry with anti-IDUA antibody 
showed the presence of the enzyme in various brain regions, however an extensive 
inflammatory reaction was noted, both at the sites of implantation and in the immediate 
vicinity. This may be the reason why histological correction of lysosomal inclusions has 
not been observed.  
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Fig. 6. Microcapsules used for the treatment of MPS I mice. Left upper panel: 
photomicrography of alginate beads containing recombinant BHK that overexpress IDUA 
(small round dots). Right upper panel: Macroscopic aspect of the microcapsules (black dots) 
in a 96-well plate. Capsules were ink stained to help visualization. Lower panel: Aspect of 
the capsules in the peritoneum ten days after implantation. Note that some capsules are 
attached to the intestine. 
3.4 Transposon-based systems 
For human gene therapy we can enumerate some important aspects of transposon systems 
(special emphasis in this chapter will be given to the sleeping beauty transposon) that make 
them appealing as a vector: (1) the integrated gene has stable expression, providing long-
lasting expression of a therapeutic gene, which, as already mentioned, is essential for 
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lysosomal storage diseases; (2) the transposase directs the integration of single copies of a 
DNA sequence into chromatin and (3) the system is binary (the transposon is not 
autonomous or able to transpose on its own) (Hacket et al, 2005). 
The most studied transposon system, which has been used in pre-clinical studies for 
treatment of lysosomal disorders, is the Sleeping beauty (SB) system. Sleeping beauty 
transposon is a type of mobile element that belongs to the Tc1/Mariner class and that is able 
to transpose via movement of a DNA element in a simple cut-and-paste manner. For that, a 
precise piece of DNA is excised from one DNA molecule and moved to another site in the 
same or in a different DNA molecule (Plasterk, 1993). This reaction is catalyzed by the 
protein transposase, which can be supplied in trans by another plasmid for gene therapy 
purposes. 
The SB transposon system consists of two components: (i) a transposon, made up of the 
gene of interest flanked by inverted repeats (IRs), and (ii) a source of transposase (figure 
7). For Sleeping Beauty-mediated transposition, the transposase can recognize the ends of 
the IRs, excises the gene of interest from the delivered plasmid DNA, and then inserts it 
into another DNA site. Based on studies in about 2,000 integration events in either mouse 
or human genomes, transposons seem to integrate into random sites, including exons, 
introns and intergenic sequences (Carlson et al, 2003;  Horie et al, 2003; Hacket et al, 2005). 
This is a potential problem, since it may lead to an event of insertional mutagenesis.  A 
complete list of insertion positions of the SB tranposon can be found at the Mouse 
Transposon Insertion database at http://mouse.ccgb.umn.edu/transposon/ (Roberg-
Perez et al, 2003). 
The use of SB transposons as gene therapy approach in LSD is still recent. The first 
published work was conducted by Aronovich et al (2007) who studied the effects of 
intravenous hydrodynamic injection of the SB transposon into mice with 
Mucopolysaccharidosis types I or VII. Without immunomodulation, initial enzyme 
activities in plasma reached levels higher than 100-fold that of wild-type (WT). However, 
both GUSB (MPS VII) and IDUA (MPS I) levels fell to background within 4 weeks post-
injection.  
A second group of animals was performed with immunomodulation only in MPS I mice. 
Plasma IDUA persisted for over 3 months at up to 100-fold WT activity in one-third of the 
mice, which was sufficient to reverse lysosomal pathology in the liver and, partially,  
in distant organs. Histological and immunohistochemical examination of liver sections  
in IDUA transposon-treated WT mice revealed inflammation 10 days post-injection 
consisting predominantly of mononuclear cells, which can be seen as a potential  
side-effect. 
A posterior study by the same group (Aronovich et al, 2009) was performed in another MPS 
I strain, which is immunodeficient (NOD/SCID mice). Using the same approach from the 
previous experiment, they were able to show a persistent elevation (100-fold normal) in the 
plasma IDUA levels for 18 weeks. Also, IDUA activity was present in all organs analyzed, 
including the brain. The SB transposon system proved efficacious in correcting several 
clinical manifestations of MPS I mice, including bone abnormalities, hepatomegaly, and 
accumulation of foamy macrophages in bone marrow and synovium. In 2008 the first 
human clinical trial using the SB transposon was approved in the USA for treatment of 
cancer (Williams, 2008), however although promising no clinical trials have been conducted 
in LSDs so far. 
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Fig. 7. SB transposon system. This simplified version of the SB transposon system shows the 
cut-and-paste system used by the SB transposase to insert the DNA into the host genome. 
The gene of interest is flanked by two inverted repeats regions (IRs, arrows) which will be 
recognized by the transposase (usually given in trans in a second plasmid) and allow the 
transgene to be inserted into the host genome. This way only the transgene will have 
prolonged expression, as transposase gene expression is transient. The SB transposon is a 
non-viral method of gene delivery that allows integration of the transgene in the host cell. 
3.5 Minicircle gene therapy 
Sustained in vivo transgene expression from plasmids can be difficult to achieve due to gene 
silencing. The mechanism by which this process occurs was postulated to be due to the 
deposition of repressive heterochromatin on the noncoding bacterial backbone sequences 
required for plasmid bacterial preparation and propagation (Chen et al, 2008; Riu et al, 2005). 
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Based on those findings, a new technology has emerged, known as the minicircle (MC) gene 
therapy. This system uses a phiC31 integrase recombination event to remove the bacterial 
backbone elements of the plasmid resulting in a DNA circle (the MC), encoding the 
mammalian expression cassette of choice and a small attR footprint (Chen et al, 2003). This 
has proven to be resistant to gene silencing in vivo, is maintained as an extrachromosomal 
episome, and therefore represents an interesting platform for gene replacement strategies 
for lysosomal storage disorders (figure 8). 
This technology was recently used for treatment of MPS I mice in a proof-of-concept study 
(Osborn et al, 2011). In this study, the researchers performed a hydrodynamic injection of a 
minicircle plasmid containing the IDUA gene combined with immunomodulation, 
achieving stable expression of the transgene, increased IDUA tissue levels and reduction in 
GAG storage. As a recent technology, this is the only study performed on LSDs so far, but 
results are encouraging and should be tested on other diseases soon. 
 
 
Fig. 8. Production of a minicircle plasmid. This simplified version of the process shows the 
parental plasmid containing both the gene of interest and the bacterial components, 
including origin of replication (ORI), genes that confer resistance to antibiotic (Ab resist) and 
sites that allow attachment of the integrase (att B and P). After activation of the integrase, a 
cis-recombination event occurs, separating the gene of interest and its regulatory elements 
from the bacterial backbone, which then is degraded.  
4. Conclusions 
Still nowadays most lysosomal storage disorders do not have an effective treatment. 
Moreover, treatments currently available are not able to correct all the manifestations of 
these multisystemic diseases. Despite the small number of protocols (if compared to other 
areas, like oncology), gene therapy approaches have shown their potential to be helpful in 
many of these diseases. Not only proof of concept experiments have been performed, but 
clinically relevant results were obtained in some cases.  
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The limitations of non-viral gene transfer, i.e., transient expression of the transgene and low 
transfection efficiency, are being slowly overcome in the last decade using improved vector 
design and techniques, such as nanotechnology, transposons, and minicircle approaches (to 
name a few) as demonstrated throughout this chapter. Novel mechanisms to help the DNA 
to escape endosomal degradation and pass through the nuclear envelope are also under 
development but were not in the scope of this chapter. Nevertheless, these improvements 
help non-viral gene therapy to move towards clinical trials in LSDs, which are expected to 
happen in the years to come. Non-viral vectors are safer than viral particles, which make 
them an appealing alternative for treatment of lysosomal storage disorders and even other 
monogenic diseases. Yet, there is a long way to clinical application but the road is paved and 
the scientific community advances steadily. 
5. Acknowledgements  
The authors are thankful to Conselho Nacional de Desenvolvimento Cientifico- CNPq and  
Fundacao de Amparo a Pesquisa do Rio Grande do Sul- FAPERGS.  
We also would like to thank our colleagues Fabiana Quoos Mayer, Carlos Oscar Kieling, 
Valeska Lizzi Lagranha and Raquel Balestrin for contributing with data to this paper. 
6. References  
Al-Dosari, M.S., Gao X. (2009). Nonviral gene delivery: principle, limitations, and recent 
progress. AAPS J, Vol 11, No 4, pp 671-681. 
Anson, D.S., Bielicki, J., Hopwood, J.J. (1992). Correction of mucopolysaccharidosis type I 
fibroblasts by retroviral-mediated transfer of the human alpha-L-iduronidase gene. 
Hum Gene Ther, Vol 3, No 4, pp 371-379. 
Aronovich, E.L., Bell, J.B., Belur, L.R., Gunther, R., Koniar, B., Erickson, D.C., Schachern, P.A., 
Matise, I., McIvor, R.S., Whitley, C.B., Hackett, P.B. (2007) Prolonged expression of a 
lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene 
delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene 
Med, Vol 9, No 5, pp 403-415. 
Aronovich EL, Bell JB, Khan SA, Belur LR, Gunther R, Koniar B, Schachern PA, Parker JB, 
Carlson CS, Whitley CB, McIvor RS, Gupta P, Hackett PB. (2009) Systemic correction 
of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon 
system. Mol Ther.Vol 17, No 7, pp 1136-1144. 
Baiotto, C., Sperb, F.,  Matte ,U., Silva, C.D., Sano, R., Coelho, J.C., Giugliani, R. (2011) Population 
analysis of the GLB1 gene in south Brazil. Gen Mol Biol, Vol 34, No 1, pp 45-48. 
Baldo, G., Quoos Mayer, F., Burin, M., Carrillo-Farga, J., Matte, U., Giugliani, R. (2011) 
Recombinant Encapsulated Cells Overexpressing Alpha-L-Iduronidase Correct 
Enzyme Deficiency in Human Mucopolysaccharidosis Type I Cells. Cells Tissues 
Organs, epub. 
Balestrin, R.C., Baldo, G., Vieira, M.B., Sano, R., Coelho, J.C., Giugliani, R., Matte, U. (2008) 
Transient high-level expression of beta-galactosidase after transfection of fibroblasts 
from GM1 gangliosidosis patients with plasmid DNA. Braz J Med Biol Res, Vol 41, No 
4, PP 283-288. 
Barsoum, S.C., Milgram, W., Mackay, W., Coblentz, C., Delaney, K.H., Kwiecien, J.M., Kruth, 
S.A., Chang P.L. (2003) Delivery of recombinant gene product to canine brain with 
the use of microencapsulation. J Lab Clin Med, Vol 142, No 6, pp 399-413. 
www.intechopen.com
 Non-Viral Gene Therapy 
 
164 
Bellettato, C.M., Scarpa, M. (2010) Pathophysiology of neuropathic lysosomal storage 
disorders. J Inherit Metab Dis, Vol 33, No4, PP 347-362. 
Bloch, J., Bachoud-Lévi, A.C., Déglon, N., Lefaucheur, J.P., Winkel, L., Palfi, S., Nguyen, J.P., 
Bourdet, C., Gaura, V., Remy, P., Brugières, P., Boisse, M.F., Baudic, S., Cesaro, P., 
Hantraye, P., Aebischer, P., Peschanski, M. (2004). Neuroprotective gene therapy for 
Huntington's disease, using polymer-encapsulated cells engineered to secrete human 
ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther, Vol 15, No 10, 
pp 968-975. 
Bressel, T., Paz, A.H., Baldo, G., Lima, E.O.C., Matte, U., Saraiva-Pereira, M. (2008) An effective 
device for generating alginate microcapsules. Genet. Mol. Biol, Vol  31, No 1, pp 136-140. 
Brunetti-Pierri, N., Stapleton, G.E., Palmer, D.J., Zuo, Y., Mane, V.P., Finegold, M.J., Beaudet, 
A.L., Leland, M.M., Mullins, C.E., Ng, P. (2007) Pseudo-hydrodynamic delivery of 
helper-dependent adenoviral vectors into non-human primates for liver-directed gene 
therapy. Mol Ther, Vol 15, No4, pp 732- 740. 
Camassola, M., Braga, L.M., Delgado-Cañedo, A., Dalberto, T.P., Matte, U., Burin, M., Giugliani, 
R., Nardi, N.B. (2005) Nonviral in vivo gene transfer in the mucopolysaccharidosis I 
murine model. J Inherit Metab Dis, Vol 28, No 6, pp 1035-1043. 
Carlson, C.M., Dupuy, A.J., Fritz, S., Roberg-Perez, K.J., Fletcher, C.F., Largaespada, D.A. (2003) 
Transposon mutagenesis of the mouse germline. Genetics Vol 165, No 1 pp 243–256.  
Chen, Z.Y., He, C.Y., Ehrhardt, A. and Kay, M.A. (2003) Minicircle DNA vectors devoid of 
bacterial DNA result in persistent and high-level transgene expression in vivo. Mol 
Ther, Vol 8, No 3, pp 495–500. 
Chen, Z.Y., Riu, E., He, C.Y., Xu, H. and Kay, M.A. (2008) Silencing of episomal transgene 
expression in liver by plasmid bacterial backbone DNA is independent of CpG 
methylation. Mol Ther, Vol 16, No 3, pp 548–556. 
Consiglio, A., Martino, S., Dolcetta, D. (2007) Metabolic correction in oligodendrocytes derived 
from metachromatic leukodystrophy mouse model by using encapsulated 
recombinant myoblasts. J Neurol  Sci, Vol 255, No 1-2, pp 7-16. 
Dass, C.R.(2004) Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo 
transfection. J Mol Med, Vol 82, No 9, pp 579–591. 
de Duve, C. (1964) From cytases to lysosomes. Fed Proc, Vol 23, pp 1045–1049. 
Dunbar, C.E., Kohn, D.B., Schiffmann, R., Barton, N.W., Nolta, J.A., Esplin, J.A., Pensiero, M., 
Long, Z., Lockey, C., Emmons, R.V., Csik, S., Leitman, S., Krebs, C.B., Carter, C., 
Brady, R.O., Karlsson, S. (1998) Retroviral transfer of the glucocerebrosidase gene into 
CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells 
without myeloablation. Hum Gene Ther, Vol 9, No 17, pp 2629-2640. 
Ellinwood, N.M., Vite, C.H., Haskins, M.E. (2004) Gene therapy for lysosomal storage diseases: 
the lessons and promise of animal models. J Gene Med. Vol 6, No 5, pp 481-506. 
Estruch, E.J., Hart, S.L., Kinnon, C., Winchester, B.G. (2001) Non-viral, integrin-mediated gene 
transfer into fibroblasts from patients with lysosomal storage diseases. J Gene Med, 
Vol 3, No 5, pp 488-497. 
Fischer, H.D., Gonzalez-Noriega, A., Sly, W.S., Morre, D.J. (1980) Phosphomannosyl-enzyme 
receptors in rat liver. Subcellular distribution and role in intracellular transport of 
lysosomal enzymes. J Biol Chem. Vol 255, No 20, pp 9608–15. 
Fraga, M., Laux, M., Zandoná, B., Santos, G.R., Giuberti, C.S., Oliveira, M.C., Matte, U., 
Teixeira, H.F. (2008) Optimization of stearylamine-based nanoemulsions obtained by 
spontaneous emulsification process as nucleic acids delivery systems. J Drug Del Sci 
Tech Vol 18, No 6, pp 398-403.  
www.intechopen.com
 Non Viral Gene Transfer Approaches for Lysosomal Storage Disorders 
 
165 
Fraga, M., Bruxel, F., Lagranha, V., Teixeira, H.F., Matte, U. Influence of phospholipid 
composition on DNA/cationic emulsions complexes: Physicochemical properties, 
cytotoxicity and transfection on Hep G2 cells. International Journal of Nanomedicine, in 
press. 
Fratantoni, J.C., Hall, C.W., Neufeld, E.F. (1968) Hurler and Hunter syndromes: mutual 
correction of the defect in cultured fibroblasts. Science, Vol 162, No 853, pp 570–572. 
Friso, A., Tomanin, R., Alba, S. (2005) Reduction of GAG storage in MPS II mouse model 
following implantation of encapsulated recombinant myoblasts. J Gene Med, Vol 7, No 
11, pp 1482-1491. 
Fuller, M., Meikle, P.J., Hopwood, J.J. (2006) Epidemiology of lysosomal storage diseases: an 
overview. In Fabry Disease: Perspectives from 5 Years of FOS. Mehta A, Beck M, Sunder-
Plassmann G, editors. Oxford: Oxford PharmaGenesis.  
Glover D, Lipps H, Jans D (2005) Towards safe, non-viral therapeutic gene expression in 
humans. Nature Reviews Genetics, Vol 6, No 4, 299-310. 
Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., 
Caccavelli, L., Delabesse, E., Beldjord, K., Asnafi, V., MacIntyre, E., Dal Cortivo, L., 
Radford, I., Brousse, N., Sigaux, F., Moshous, D., Hauer, J., Borkhardt, A., 
Belohradsky, B.H., Wintergerst, U., Velez, M.C., Leiva, L., Sorensen, R., Wulffraat, N., 
Blanche, S., Bushman, F.D., Fischer, A., Cavazzana-Calvo, M. (2008) Insertional 
oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin 
Invest, Vol 118, No 9, pp 3132-3142. 
Hackett, P.B., Ekker, S.C., Largaespada, D.A., McIvor, R.S. (2005) Sleeping beauty transposon-
mediated gene therapy for prolonged expression. Adv Genet, Vol 54, pp 189-232. 
Horie, K., Yusa, K., Yae, K., Odajima, J., Fischer, S. E., Keng, V. W., Hayakawa, T., Mizuno, S., 
Kondoh, G., Ijiri, T., Matsuda, Y., Plasterk, R. H., and Takeda, J. (2003) 
Characterization of Sleeping Beauty transposition and its application to genetic 
screening in mice. Mol. Cell. Biol, Vol 23, No 24,  pp 9189–9207. 
Hunter, C. (2006) Molecular hurdles in polyfectin design and mechanistic background to 
polycation induced cytotoxicity. Advanced Drug Delivery Reviews, Vol 58, pp 1523–1531. 
Kamimura, K., Zhang, G., Liu, D. (2009) Image-guided, intravascular hydrodynamic gene 
delivery to skeletal muscle in pigs. Mol Ther, Vol 18, No 1, pp 93-100. 
Kuijlen, J.M., de Haan, B.J., Helfrich, W., de Boer, J.F., Samplonius, D., Mooij, J.J., de Vos, P. 
(2006) The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer 
cells in the treatment of brain tumors. J Neurooncol Vol 78, No 1, pp 31-39. 
Lagranha, V.L., Baldo, G., de Carvalho, T.G. Burin M, Saraiva-Pereira, M.L., Matte, U., 
Giugliani, R. (2008) In vitro correction of ARSA deficiency in human skin fibroblasts 
from metachromatic leukodystrophy patients after treatment with microencapsulated 
recombinant cells. Metab Brain Dis Vol 23, No 4, pp 469-84.  
Liu, F., Song, Y., Liu, D. (1999) Hydrodynamics-based transfection in animals by systemic 
administration of plasmid DNA. Gene Ther, Vol 6, No 7, pp 1258-1266. 
Malatack, J.J., Consolini, D.M., Bayever, E. (2003) The status of hematopoietic stem cell 
transplantation in lysosomal storage disease. Pediatr Neurol, Vol 29, No 5, pp 391-403. 
Matte U, de Carvalho T, Mayer F, Lagranha V, Giugliani R. (2011) Cell Microencapsulation: a 
Potential Tool for the Treatment of Neuronopathic Lysosomal Storage Diseases. 
Journal of Inherited Metabolic Diseases, epub. 
Mayer, F.Q., Baldo, G., de Carvalho, T.G., Lagranha, V.L., Giugliani, R., Matte, U. (2010) Effects 
of cryopreservation and hypothermic storage on cell viability and enzyme activity in 
www.intechopen.com
 Non-Viral Gene Therapy 
 
166 
recombinant encapsulated cells overexpressing alpha-L-iduronidase. Artif Organs, 
Vol 34, No 5, pp 434-439.  
Meikle, P.J., Fietz, M.J., Hopwood, J.J. (2004) Diagnosis of lysosomal storage disorders: current 
techniques and future directions. Expert Rev Mol Diagn. Vol 4, No 5, pp 677–691. 
Moreira, J., Gaspar, R., Allen T. (2001) Targeting Stealth liposomes in a murine model of 
human small cell lung cancer. Biochimica et Biophysica Acta, Vol 1515, pp 167-176. 
Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A., Benoit, J.P. (2008) Progress in 
developing cationic vectors for non-viral systemic gene therapy against cancer. 
Biomaterials, Vol, 29, No 24-25, pp 3477-3496.  
Muñoz-Rojas, M.V., Horovitz, D.D., Jardim, L.B., Raymundo, M., Llerena, J.C. Jr, de 
Magalhães, T.S., Vieira, T.A., Costa, R., Kakkis, E., Giugliani, R. (2010) Intrathecal 
administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI 
patient with pachymeningitis cervicalis. Mol Genet Metab, Vol 99, No 4, pp 346-350. 
Munoz-Rojas, M.V., Vieira, T., Costa, R., Fagondes, S., John, A., Jardim, L.B., Vedolin, L.M., 
Raymundo, M., Dickson, P.I., Kakkis, E., Giugliani, R. (2008) Intrathecal enzyme 
replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic 
spinal cord compression. Am J Med Genet A, Vol 146A, Vol 19, pp 2538-2544. 
Muro, S. (2010) New biotechnological and nanomedicine strategies for treatment of lysosomal 
storage disorders. Wiley Interdiscip Rev Nanomed Nanobiotechnol, Vol 2, No 2, pp 189- 
204. 
Naganawa, Y., Ohsugi, K., Kase, R., Date, I., Sakuraba, H., Sakuragawa, N. (2002) In vitro 
study of encapsulation therapy for Fabry disease using genetically engineered CHO 
cell line. Cell Transplant, Vol 11, No 4, pp 325-329. 
Nakama, H, Ohsugi, K, Otsuki, T., Date, I., Kosuga, M., Okuyama, T., Sakuragawa, N. (2006) 
Encapsulation cell therapy for mucopolysaccharidosis type VII using genetically 
engineered immortalized human amniotic epithelial cells. Tohoku J Exp Med, Vol 209, 
No 1, pp 23-32.  
Nam, H.Y., Park, J.H., Kim, K., Kwon, I.C., Jeong, S.Y. (2009) Lipid-based emulsion system as 
non-viral gene carriers. Arch Pharm Res Vol 32, No 5, pp 639-646.  
Niidome, T. and Huang, L. (2002) Gene Therapy Progress and Prospects: Nonviral vectors. 
Gene Therapy Vol 9, No 24, pp 1647–1652. 
Orive, G., Ponce, S., Hernandez, R.M., Gascon, A.R., Igartua, M., Pedraz, J.L. (2002) 
Biocompatibility of microcapsules for cell imobilization alaborated with different type 
of alginates. Biomaterials Vol 23, No 18, pp 3825-3831. 
Orive, G., Gascon, R.A., Hernandez, R.M., Igartua, M., Pedraz, J.L. (2003) Cell 
microencapsulation technology for biomedical purposes: novel insights and 
challenges. Trends in Pharmacological Sciences, Vol 24, No 5, pp 207-210. 
Osborn, M.J., McElmurry, R.T., Peacock, B., Tolar, J., Blazar, B.R. (2008) Targeting of the CNS 
in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product. Mol 
Ther, Vol 16, No 8, pp 1459-1466. 
Osborn, M.J., McElmurry, R.T., Lees, C.J., Defeo, A.P., Chen, Z.Y., Kay, M.A., Naldini, L., 
Freeman, G., Tolar, J., Blazar, B.R. (2011) Minicircle DNA-based Gene Therapy Coupled 
With Immune Modulation Permits Long-term Expression of ǂ-L-Iduronidase in Mice 
With Mucopolysaccharidosis Type I. Mol Ther, 2011 Vol 19, No 3, pp 450-460. 
Pardridge, W.M. (2007) Blood-brain barrier delivery of protein and non-viral gene therapeutics 
with molecular Trojan horses. J Control Release, Vol 122, No 3, pp 345-348.  
www.intechopen.com
 Non Viral Gene Transfer Approaches for Lysosomal Storage Disorders 
 
167 
Parkinson-Lawrence, E.J., Shandala, T., Prodoehl, M., Plew, R., Borlace, G.N., Brooks, D.A. (2010) 
Lysosomal storage disease: revealing lysosomal function and physiology. Physiology 
(Bethesda), Vol 25, No 2, pp 102-115. 
Plasterk, R.H. (1993) Molecular mechanisms of transposition and its control. Cell, Vol 74, No 5, 
pp 781–786. 
Ragnaill, M.N., Brown, M., Ye, D., Bramini, M., Callanan, S., Lynch, I., Dawson, K.A. (2011) 
Internal benchmarking of a human blood-brain barrier cell model for screening of 
nanoparticle uptake and transcytosis. Eur J Pharm Biopharm. Vol 77, No 3, pp 360-367. 
Resina, S., Prevot, P., Thierry, A.R. (2009) Physico-chemical characteristics of lipoplexes influence 
cell uptake mechanisms and transfection efficacy. PLoS One Vol 4, No 6, e6058. 
Richard, M., Arfi, A., Seguin, J., Gandolphe, C., Scherman, D. (2009) Widespread biochemical 
correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic 
plasmid delivery. Gene Ther, Vol 16, No 6, pp 746-756. 
Riu, E., Grimm, D., Huang, Z. and Kay, M.A. (2005). Increased maintenance and persistence of 
transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum 
Gene Ther Vol 16, No 5, pp 558–570. 
Roberg-Perez, K., Carlson, C.M., Largaespada, D.A. (2003) MTID: a database of Sleeping 
Beauty transposon insertions in mice. Nucleic Acids Res, Vol 31, No 1, pp 78-81. 
Ross, C.J., Bastedo, L., Maier, S.A., Sands, M.S., Chang, P.L. (2000a) Treatment of a lysosomal 
storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant 
cells. Hum Gene Ther, Vol 11, No 15, pp 2117-2127. 
Ross, C.J., Ralph, M., Chang, P.L. (2000b) Somatic gene therapy for a neurodegenerative disease 
using microencapsulated recombinant cells. Exp Neurol, Vol 166, No 2, pp 276-286.  
Sifuentes, M., Doroshow, R., Hoft, R., Mason, G., Walot, I., Diament, M., Okazaki, S., Huff, K., 
Cox, G.F., Swiedler, S.J., Kakkis, E.D. (2007) A follow-up study of MPS I patients treated 
with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab, Vol 90, No 2, 
pp 171-180. 
Skarlatos, S., Yoshikawa, T., Pardridge, W.M. (1995) Transport of [125I]transferrin through the rat 
blood-brain barrier. Brain Res, Vol 683, No 2, pp 164-171. 
Sly, W.S., Fischer, H.D., Gonzalez-Noriega, A., Grubb, J.H., Natowicz, M. (1981) Role of the 6-
phosphomannosyl-enzyme receptor in intracellular transport and adsorptive 
pinocytosis of lysosomal enzymes. Methods Cell Biol, Vol 23, pp 191-214.  
Spuch. C., Antequera, D., Portero, A., Orive, G., Hernández, R.M., Molina, J.A., Bermejo-
Pareja, F., Pedraz, J.L., Carro, E. (2010) The effect of encapsulated VEGF-secreting 
cells on brain amyloid load and behavioral impairment in a mouse model of 
Alzheimer's disease. Biomaterials, Vol 31, No21, pp 5608-5618. 
Takakusaki, Y., Hisayasu, S., Hirai, Y., Shimada, T. (2005) Coexpression of formylglycine-
generating enzyme is essential for synthesis and secretion of functional arylsulfatase 
A in a mouse model of metachromatic leukodystrophy. Hum Gene Ther, Vol 16, No 8, 
pp 929-936. 
Tomanin, R., Friso, A., Alba, S., Piller Puicher, E., Mennuni, C., La Monica, N., Hortelano, G., 
Zacchello, F., Scarpa M. (2002) Non-viral transfer approaches for the gene therapy of 
mucopolysaccharidosis type II (Hunter syndrome). Acta Paediatr Suppl, Vol 91, No 
439, pp 100-104. 
Uludag, H., Vos, P., Tresco, P. (2000) Technology of mammalian cell encapsulation. Adv Drug 
Delivery Reviews, Vol 42, No 1-2, pp 29-64. 
Vitner, E.B., Platt, F.M., Futerman, A.H. (2010) Common and uncommon pathogenic cascades 
in lysosomal storage diseases. J Biol Chem, Vol 285, No 27, pp 20423-20427.  
www.intechopen.com
 Non-Viral Gene Therapy 
 
168 
Walkley, S.U. (2009) Pathogenic cascades in lysosomal disease-Why so complex? J Inherit 
Metab Dis, Vol 32, No 2, pp 181-189. 
Wasungu, L., Hoekstra, D. (2006) Cationic lipids, lipoplexes and intracellular delivery of genes. 
Journal of Controlled Release, Vol. 116, No 2, pp 255-264. 
Williams, D.A. (2008). Sleeping beauty vector system moves toward human trials in the United 
States. Mol Ther, Vol 16, No 9, pp 1515-1516. 
Wilson JM. (2009) Lessons learned from the gene therapy trial for ornithine transcarbamylase 
deficiency. Mol Genet Metab,Vol 96, No 4, pp 151-157. 
Worgall, S., Sondhi, D., Hackett, N.R., Kosofsky, B., Kekatpure, M.V., Neyzi, N., Dyke, J.P., 
Ballon, D., Heier, L., Greenwald, B.M., Christos, P., Mazumdar, M., Souweidane, 
M.M., Kaplitt, M.G., Crystal, R.G. (2008) Treatment of late infantile neuronal ceroid 
lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus 
expressing CLN2 cDNA. Hum Gene Ther, Vol 19, No 5, pp 463-474. 
Zhang, Y., Wang, Y., Boado, R.J., Pardridge, W.M. (2007) Lysosomal enzyme replacement of 
the brain with intravenous non-viral gene transfer. Pharm Res, Vol 25, No 2, pp 400-
406. 
www.intechopen.com
Non-Viral Gene Therapy
Edited by Prof. Xubo Yuan
ISBN 978-953-307-538-9
Hard cover, 696 pages
Publisher InTech
Published online 07, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book focuses on recent advancement of gene delivery systems research. With the multidisciplinary
contribution in gene delivery, the book covers several aspects in the gene therapy development: various gene
delivery systems, methods to enhance delivery, materials with modification and multifunction for the tumor or
tissue targeting. This book will help molecular biologists gain a basic knowledge of gene delivery vehicles,
while drug delivery scientist will better understand DNA, molecular biology, and DNA manipulation.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Ursula Matte, Guilherme Baldo and Roberto Giugliani (2011). Non Viral Gene Transfer Approaches for
Lysosomal Storage Disorders, Non-Viral Gene Therapy, Prof. Xubo Yuan (Ed.), ISBN: 978-953-307-538-9,
InTech, Available from: http://www.intechopen.com/books/non-viral-gene-therapy/non-viral-gene-transfer-
approaches-for-lysosomal-storage-disorders
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
